Behcet Disease.

Behcet disease is a chronic inflammatory condition affecting blood vessels of all sizes, causing recurrent mouth and genital ulcers, eye inflammation, skin lesions, and sometimes joint, vascular, gut, or brain involvement. It is most common in countries along the historic Silk Road.

Hallmark symptoms are recurrent painful oral and genital ulcers, eye inflammation (uveitis), pustular skin lesions, and arthritis. Some patients also have deep vein thrombosis, intestinal ulcers, or neurological involvement. Symptoms typically come in flares lasting weeks to months.

Diagnosis is clinical, based on International Criteria for Behcet's Disease (ICBD 2014) requiring recurrent oral ulcers plus features such as genital ulcers, eye lesions, skin lesions, vascular involvement, or positive pathergy test. HLA-B*51 testing supports the diagnosis in equivocal cases.

Behcet disease has features of both autoimmune and autoinflammatory diseases. It involves dysregulated innate immunity (hyperactive neutrophils) and adaptive immunity (Th1 and Th17 cells) without specific autoantibodies seen in classical autoimmune diseases like lupus.

Behcet disease is caused by complex interactions between genetic factors (especially HLA-B*51) and environmental triggers including streptococcal antigens, herpes simplex virus, and oral microbial dysbiosis. No single cause has been identified.

Treatment is organ-specific. Mucocutaneous and joint disease respond to colchicine, apremilast, and corticosteroids. Ocular, vascular, neurological, and gastrointestinal involvement require immunosuppression with azathioprine, cyclosporine, interferon-alpha, or TNF-alpha inhibitors. Treatment is lifelong.

There is no cure for Behcet disease, but it can be effectively controlled. Most patients achieve symptom relief and prevention of major organ damage with modern immunosuppression. Disease activity typically declines after the first 7 years; some patients enter prolonged remission.

Genetic factors contribute but Behcet is not inherited in a Mendelian pattern. HLA-B*51 carriage increases risk 5-7 fold but is not necessary or sufficient. Family clustering is common but most patients have no affected relatives. Multiple susceptibility genes interact with environmental factors.

Behcet disease is most common along the historic Silk Road from the Mediterranean to East Asia. Prevalence is highest in Turkey (80-420 per 100,000), Iran, Iraq, Japan, and Korea. It is uncommon in northern Europe and North America, though under-recognized in migrant populations.

Ocular Behcet historically caused blindness in 25% of patients within 5 years. Modern treatment with biologic therapies has reduced this risk to under 5% in specialist centers. Early diagnosis and aggressive immunosuppression are key to preserving vision.

The pathergy test involves a sterile needle prick of the forearm skin. A positive result is a sterile pustule developing within 24-48 hours, indicating hyperreactivity to minor trauma. The test is highly specific but variably sensitive, with higher positivity rates in Mediterranean and East Asian patients.

HLA-B*51 increases susceptibility 5-7 fold but does not directly cause Behcet. It is carried by 50-70% of patients in endemic countries versus 10-20% of healthy individuals. Other genetic and environmental factors are necessary for disease expression.

Yes. Neurological Behcet (neuro-Behcet) affects 5-15% of patients and can produce brainstem syndromes, hemiparesis, cerebellar ataxia, seizures, behavioral changes, and cerebral venous sinus thrombosis. Treatment requires high-dose immunosuppression including TNF-alpha inhibitors in severe cases.

Yes. Colchicine 0.5-1.5 mg daily reduces oral and genital ulcer frequency in 50-70% of patients and is particularly effective in women. It is first-line for mucocutaneous and articular disease. Side effects (diarrhea, abdominal cramps) may limit dose escalation.

Apremilast is a phosphodiesterase 4 inhibitor taken 30 mg twice daily and FDA-approved (2019) for Behcet's oral ulcers. It significantly reduces oral ulcer count in randomized trials (RELIEF) with response in 65-75% of patients at 12 weeks. Side effects include diarrhea, nausea, and headache.

Pregnancy outcomes are generally favorable when disease is controlled. Some patients experience flares during pregnancy or postpartum; others enter remission. Medication review is essential to avoid teratogens (thalidomide, methotrexate, mycophenolate). Azathioprine, hydroxychloroquine, and certain biologics can be continued.

Mucocutaneous Behcet has an excellent prognosis with normal life expectancy. Ocular Behcet, vascular, neurological, and gastrointestinal involvement carry higher morbidity and mortality. Standardized mortality ratio is 1.4-1.7 in Turkish cohorts. Young men with severe systemic involvement have the worst outcomes.

Yes. Vascular Behcet causes deep vein thrombosis, superficial thrombophlebitis, Budd-Chiari syndrome, and cerebral venous sinus thrombosis in 15-40% of patients. Treatment combines immunosuppression with anticoagulation in most venous events, but anticoagulation is avoided in pulmonary artery aneurysms.

Yes. TNF-alpha inhibitors (infliximab, adalimumab) are highly effective for severe ocular, vascular, neurological, and gastrointestinal Behcet. Response rates are 60-80% in refractory disease. They are increasingly used as first-line for major organ involvement.

No. Behcet disease is not contagious. It cannot be transmitted between people. Genetic susceptibility and environmental triggers cause disease in predisposed individuals. Family members may be at higher risk because of shared genetics rather than transmission.

Look for a rheumatologist with documented experience in vasculitis, ideally at a tertiary center with multidisciplinary Behcet or vasculitis clinic. National patient organizations (American Behcet's Disease Association, Behcet's UK) maintain specialist directories. Multidisciplinary care improves outcomes significantly.